

Carlos Fernandez-Del Castillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10453342/publications.pdf>

Version: 2024-02-01

315
papers

37,352
citations

3731

89
h-index

3106

187
g-index

324
all docs

324
docs citations

324
times ranked

20826
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. <i>Surgery</i> , 2017, 161, 584-591.	1.9	2,655
2	Consensus statement on the pathology of IgG4-related disease. <i>Modern Pathology</i> , 2012, 25, 1181-1192.	5.5	2,171
3	International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. <i>Pancreatology</i> , 2012, 12, 183-197.	1.1	2,043
4	International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas. <i>Pancreatology</i> , 2006, 6, 17-32.	1.1	1,805
5	Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. <i>Nature</i> , 2003, 425, 851-856.	27.8	1,395
6	Pancreatic Carcinoma. <i>New England Journal of Medicine</i> , 1992, 326, 455-465.	27.0	1,391
7	Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. <i>Pancreatology</i> , 2017, 17, 738-753.	1.1	1,208
8	Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2015, 261, 12-17.	4.2	717
9	Main-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2004, 239, 678-687.	4.2	681
10	Cystic Neoplasms of the Pancreas. <i>New England Journal of Medicine</i> , 2004, 351, 1218-1226.	27.0	674
11	Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. <i>Arthritis and Rheumatism</i> , 2012, 64, 3061-3067.	6.7	630
12	Incidental Pancreatic Cysts. <i>Archives of Surgery</i> , 2003, 138, 427.	2.2	515
13	Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 2897-2902.	1.6	487
14	International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. <i>Pancreatology</i> , 2018, 18, 2-11.	1.1	452
15	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 963.	7.1	426
16	Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. <i>Gastroenterology</i> , 2007, 133, 72-79.	1.3	422
17	Standards for Pancreatic Resection in the 1990s. <i>Archives of Surgery</i> , 1995, 130, 295.	2.2	420
18	Mucinous Cystic Neoplasm of the Pancreas is Not an Aggressive Entity. <i>Annals of Surgery</i> , 2008, 247, 571-579.	4.2	407

#	ARTICLE	IF	CITATIONS
19	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	1.3	376
20	Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2017, 265, 185-191.	4.2	366
21	851 resected cystic tumors of the pancreas: A 33-year experience at the Massachusetts General Hospital. <i>Surgery</i> , 2012, 152, S4-S12.	1.9	355
22	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	7.1	353
23	Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 257, 731-736.	4.2	344
24	Cystic Pancreatic Lesions: A Simple Imaging-based Classification System for Guiding Management. <i>Radiographics</i> , 2005, 25, 1471-1484.	3.3	342
25	Serous Cystadenoma of the Pancreas. <i>Annals of Surgery</i> , 2005, 242, 413-421.	4.2	341
26	Debridement and Closed Packing for Sterile or Infected Necrotizing Pancreatitis. <i>Annals of Surgery</i> , 2008, 247, 294-299.	4.2	290
27	Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 213-219.e4.	4.4	289
28	FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. <i>Oncologist</i> , 2013, 18, 543-548.	3.7	265
29	In Vivo Lineage Tracing Defines the Role of Acinar-to-Ductal Transdifferentiation in Inflammatory Ductal Metaplasia. <i>Gastroenterology</i> , 2007, 133, 1999-2009.	1.3	251
30	Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. <i>Gut</i> , 2011, 60, 1712-1720.	12.1	244
31	Risk Factors for Pancreatic Cellular Injury after Cardiopulmonary Bypass. <i>New England Journal of Medicine</i> , 1991, 325, 382-387.	27.0	235
32	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019, 269, 733-740.	4.2	235
33	Pancreatic Fistula Rates After 462 Distal Pancreatectomies: Staplers Do Not Decrease Fistula Rates. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1691-1698.	1.7	225
34	Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract. <i>Annals of Surgery</i> , 2016, 263, 162-177.	4.2	223
35	Middle Pancreatectomy. <i>Annals of Surgery</i> , 2007, 246, 69-76.	4.2	222
36	Cystic Tumors of the Pancreas. <i>Surgical Clinics of North America</i> , 1995, 75, 1001-1016.	1.5	212

#	ARTICLE	IF	CITATIONS
37	Incidental Pancreatic Cysts: Do We Really Know What We Are Watching?. <i>Pancreatology</i> , 2010, 10, 144-150.	1.1	212
38	Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine Tumors. <i>Archives of Surgery</i> , 2011, 146, 534.	2.2	208
39	Pancreatic Cystic Neoplasms: Management and Unanswered Questions. <i>Gastroenterology</i> , 2013, 144, 1303-1315.	1.3	206
40	Outcome of Pancreaticoduodenectomy With Pylorus Preservation or With Antrectomy in the Treatment of Chronic Pancreatitis. <i>Annals of Surgery</i> , 2000, 231, 293-300.	4.2	205
41	Benchmarks in Pancreatic Surgery. <i>Annals of Surgery</i> , 2019, 270, 211-218.	4.2	202
42	Intraductal Papillary Mucinous Neoplasm of Pancreas: Multi-Phase Detector Row CT with 2D Curved Reformations—Correlation with MRCP. <i>Radiology</i> , 2006, 238, 560-569.	7.3	199
43	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. <i>Gastroenterology</i> , 2017, 153, 1284-1294.e1.	1.3	189
44	Evolution of the Whipple procedure at the Massachusetts General Hospital. <i>Surgery</i> , 2012, 152, S56-S63.	1.9	188
45	Improved Contemporary Surgical Management of Insulinomas. <i>Annals of Surgery</i> , 2008, 247, 165-172.	4.2	187
46	Prevalence of Activating K-ras Mutations in the Evolutionary Stages of Neoplasia in Intraductal Papillary Mucinous Tumors of the Pancreas. <i>Annals of Surgery</i> , 1997, 226, 491-500.	4.2	183
47	Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure. <i>Surgery</i> , 2012, 152, S43-S49.	1.9	182
48	Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology guidelines. <i>Diagnostic Cytopathology</i> , 2014, 42, 338-350.	1.0	181
49	Evolving Patterns in the Detection and Outcomes of Pancreatic Neuroendocrine Neoplasms. <i>Archives of Surgery</i> , 2007, 142, 347.	2.2	180
50	Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. <i>Gut</i> , 2017, 66, 495-506.	12.1	177
51	Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. <i>Gastroenterology</i> , 2002, 122, 188-201.	1.3	172
52	Endoscopic Ultrasound Guided Fine Needle Aspiration Biopsy of Autoimmune Pancreatitis. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1464-1471.	3.7	168
53	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	7.0	168
54	Sequential Accumulation of K-ras Mutations and p53 Overexpression in the Progression of Pancreatic Mucinous Cystic Neoplasms to Malignancy. <i>Annals of Surgery</i> , 1999, 230, 501.	4.2	168

#	ARTICLE	IF	CITATIONS
55	Comparative Performance of MDCT and MRI With MR Cholangiopancreatography in Characterizing Small Pancreatic Cysts. <i>American Journal of Roentgenology</i> , 2009, 193, 722-731.	2.2	163
56	Pancreatic Duct Glands Are Distinct Ductal Compartments That React to Chronic Injury and Mediate Shh-Induced Metaplasia. <i>Gastroenterology</i> , 2010, 138, 1166-1177.	1.3	162
57	Middle Segment Pancreatectomy. <i>Archives of Surgery</i> , 1998, 133, 327-31.	2.2	157
58	Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management. <i>Radiology</i> , 2013, 266, 38-61.	7.3	156
59	Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Gastroenterology</i> , 2010, 139, 708-713.e2.	1.3	153
60	Cystic Pancreatic Endocrine Neoplasms: A Distinct Tumor Type?. <i>Journal of the American College of Surgeons</i> , 2008, 206, 1154-1158.	0.5	152
61	Pancreatic Cysts 3 cm or Smaller: How Aggressive Should Treatment Be?. <i>Radiology</i> , 2006, 238, 912-919.	7.3	149
62	Current Trends in Pancreatic Cystic Neoplasms. <i>Archives of Surgery</i> , 2009, 144, 448.	2.2	144
63	Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2016, 264, 344-352.	4.2	144
64	Diagnosis and Management of Cystic Pancreatic Lesions. <i>American Journal of Roentgenology</i> , 2013, 200, 343-354.	2.2	139
65	Cytology Adds Value to Imaging Studies for Risk Assessment of Malignancy in Pancreatic Mucinous Cysts. <i>Annals of Surgery</i> , 2011, 254, 977-983.	4.2	136
66	Pancreatic Mucinous Ductal Ectasia and Intraductal Papillary Neoplasms. <i>Annals of Surgery</i> , 1997, 225, 637-646.	4.2	133
67	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	129
68	Pancreatic cysts. <i>Cancer Cytopathology</i> , 2010, 118, 1-13.	2.4	127
69	Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. <i>Nature Cell Biology</i> , 2018, 20, 811-822.	10.3	124
70	Twenty-Three Years of the Warsaw Operation for Distal Pancreatectomy With Preservation of the Spleen. <i>Annals of Surgery</i> , 2011, 253, 1136-1139.	4.2	123
71	Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. <i>Gastroenterology</i> , 1995, 109, 239-246.	1.3	121
72	NO/N1, PNL, or LNR? The Effect of Lymph Node Number on Accurate Survival Prediction in Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 257-266.	1.7	119

#	ARTICLE	IF	CITATIONS
73	Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 140-148.	1.0	119
74	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2018, 267, 608-616.	4.2	117
75	Specific Therapy for Local and Systemic Complications of Acute Pancreatitis With Monoclonal Antibodies Against ICAM-1. <i>Annals of Surgery</i> , 1999, 229, 834.	4.2	115
76	IPMN Involving the Main Pancreatic Duct. <i>Annals of Surgery</i> , 2015, 261, 976-983.	4.2	114
77	Altered exocrine function can drive adipose wasting in early pancreatic cancer. <i>Nature</i> , 2018, 558, 600-604.	27.8	114
78	Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 15.	1.7	112
79	Implications and Cost of Pancreatic Leak Following Distal Pancreatic Resection. <i>Archives of Surgery</i> , 2006, 141, 361.	2.2	111
80	Pathogenesis and Prevention of Early Pancreatic Infection in Experimental Acute Necrotizing Pancreatitis. <i>Annals of Surgery</i> , 1995, 222, 179-185.	4.2	108
81	The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 262-276.	1.7	108
82	Cytokeratin 19 Is a Powerful Predictor of Survival in Pancreatic Endocrine Tumors. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1145-1153.	3.7	107
83	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. <i>Annals of Surgery</i> , 2018, 267, 157-163.	4.2	105
84	Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. <i>JAMA Surgery</i> , 2018, 153, 809.	4.3	103
85	A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.8	101
86	Patterns of Recurrence After Resection of IPMN. <i>Annals of Surgery</i> , 2015, 262, 1108-1114.	4.2	101
87	Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 783-794.	1.7	97
88	Trypsinogen-activation peptides in experimental rat pancreatitis: Prognostic implications and histopathologic correlates. <i>Gastroenterology</i> , 1992, 103, 1009-1016.	1.3	96
89	Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. <i>JAMA Surgery</i> , 2016, 151, 432.	4.3	95
90	Histopathological Diagnosis of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary-Mucinous Neoplasms: Interobserver Agreement. <i>Pancreas</i> , 2005, 31, 344-349.	1.1	92

#	ARTICLE	IF	CITATIONS
91	The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. <i>Surgery</i> , 2015, 157, 881-887.	1.9	91
92	Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: The PIPE Study. <i>Endoscopy</i> , 2014, 46, 382-387.	1.8	90
93	Does Size Matter in Pancreatic Cancer?. <i>Annals of Surgery</i> , 2017, 266, 142-148.	4.2	89
94	Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. <i>Surgery</i> , 2001, 129, 537-546.	1.9	86
95	Global Genomic Analysis of Intraductal Papillary Mucinous Neoplasms of the Pancreas Reveals Significant Molecular Differences Compared to Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2009, 249, 440-447.	4.2	82
96	Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2000, 7, 15-20.	2.0	79
97	Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2019, 154, 943.	4.3	79
98	Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. <i>Surgery</i> , 1997, 121, 42-49.	1.9	78
99	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2016, 48, 473-479.	0.9	78
100	Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5959-5969.	7.0	75
101	Distal pancreatectomy with splenic preservation revisited. <i>Surgery</i> , 2007, 141, 619-625.	1.9	73
102	Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1997, 21, 105-110.	0.4	72
103	Invasive Intraductal Papillary Mucinous Carcinomas of the Pancreas. <i>Annals of Surgery</i> , 2010, 251, 477-482.	4.2	69
104	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26835-26845.	7.1	69
105	Pylorus-preserving Pancreaticoduodenectomy in the Treatment of Chronic Pancreatitis. <i>World Journal of Surgery</i> , 2003, 27, 1211-1216.	1.6	68
106	Feasibility and safety of microforceps biopsy in the diagnosis of pancreatic cysts. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 79-86.	1.0	66
107	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: Implications of minimal involvement of the main pancreatic duct. <i>Surgery</i> , 2014, 156, 611-621.	1.9	65
108	Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings. <i>Journal of the American College of Surgeons</i> , 2015, 221, 699-707.	0.5	64

#	ARTICLE	IF	CITATIONS
109	Oncocytic-Type Intraductal Papillary Mucinous Neoplasms: A Unique Malignant Pancreatic Tumor with Good Long-Term Prognosis. <i>Journal of the American College of Surgeons</i> , 2015, 220, 839-844.	0.5	63
110	Mucinous Cystic Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 411-413.	1.7	61
111	Effect of Matrix Metalloproteinase Inhibition on Pancreatic Cancer Invasion and Metastasis. <i>Annals of Surgery</i> , 2000, 231, 644-654.	4.2	60
112	Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≥20-mm Invasive Component). <i>Annals of Surgery</i> , 2016, 263, 793-801.	4.2	60
113	Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN. <i>Gastroenterology</i> , 2021, 160, 1345-1358.e11.	1.3	60
114	Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 3026-3035.	4.1	59
115	Cystic pancreatic neuroendocrine tumors: The value of cytology in preoperative diagnosis. <i>Cancer Cytopathology</i> , 2014, 122, 435-444.	2.4	59
116	Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. <i>Stem Cell Research</i> , 2015, 15, 190-202.	0.7	59
117	The Inflammatory Pancreatic Head Mass. <i>Annals of Surgery</i> , 2009, 249, 105-110.	4.2	58
118	Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. <i>Cancer</i> , 2013, 119, 4196-4204.	4.1	58
119	Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2017, 266, 685-692.	4.2	57
120	Plectin-1 is a Biomarker of Malignant Pancreatic Intraductal Papillary Mucinous Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 1948-1954.	1.7	56
121	Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. <i>Journal of Pathology</i> , 2011, 224, 508-516.	4.5	56
122	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , 2019, 25, 2644-2655.	7.0	56
123	Does the Mechanism of Lymph Node Invasion Affect Survival in Patients with Pancreatic Ductal Adenocarcinoma?. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 261-267.	1.7	55
124	Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. <i>Nature Communications</i> , 2020, 11, 3303.	12.8	55
125	Immunohistochemical Characterization of Pancreatic Tumors Induced by Dimethylbenzanthracene in Rats. <i>American Journal of Pathology</i> , 1999, 154, 1223-1229.	3.8	54
126	Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1816-1823.	4.4	54

#	ARTICLE	IF	CITATIONS
127	A blinded assessment of video quality in wearable technology for telementoring in open surgery: the Google Glass experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 372-378.	2.4	54
128	Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the <scp>Massachusetts</scp> General Hospital. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 181-187.	2.6	53
129	International consensus guidelines on interventional endoscopy in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 1045-1055.	1.1	53
130	Technetium-99m-Labeled White Blood Cells. <i>Annals of Surgery</i> , 1998, 227, 86-94.	4.2	53
131	Hyperoncotic ultrahigh molecular weight dextran solutions reduce trypsinogen activation, prevent acinar necrosis, and lower mortality in rodent pancreatitis. <i>American Journal of Surgery</i> , 1993, 165, 40-45.	1.8	52
132	Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 270, 1138-1146.	4.2	50
133	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 378-385.	4.2	50
134	A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens. <i>Surgery</i> , 1997, 122, 82-90.	1.9	49
135	Interventional Radiology in the Management of Abdominal Collections After Distal Pancreatectomy: A Retrospective Review. <i>American Journal of Roentgenology</i> , 2011, 197, 241-246.	2.2	49
136	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	6.3	49
137	Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 277-283.	1.7	48
138	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2020, 168, 72-84.	1.9	48
139	Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic <i>KLF4</i> mutations predominantly in low-grade regions. <i>Gut</i> , 2021, 70, 928-939.	12.1	48
140	Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 586-593.	1.1	47
141	Increased Intrapancreatic Trypsinogen Activation in Ischemia-Induced Experimental Pancreatitis. <i>Annals of Surgery</i> , 1995, 221, 364-371.	4.2	46
142	Cystic Neoplasms of the Pancreas. <i>Pancreatology</i> , 2001, 1, 641-647.	1.1	46
143	Hypercalcemia causes acute pancreatitis by pancreatic secretory block, intracellular zymogen accumulation, and acinar cell injury. <i>American Journal of Surgery</i> , 1995, 169, 167-172.	1.8	45
144	Cystic lesions in the pancreas: When to watch, when to resect. <i>Current Gastroenterology Reports</i> , 2000, 2, 152-158.	2.5	45

#	ARTICLE	IF	CITATIONS
145	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2016, 22, 4259-4270.	7.0	44
146	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. <i>Gastroenterology</i> , 2019, 157, 720-730.e2.	1.3	44
147	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC). <i>Annals of Surgery</i> , 2019, 270, 158-164.	4.2	44
148	Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing. <i>American Journal of Gastroenterology</i> , 2019, 114, 1539-1549.	0.4	43
149	Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. <i>Surgery</i> , 2015, 158, 1219-1225.	1.9	42
150	Management of Pancreatic Cysts: The Evidence Is Not Here Yet. <i>Gastroenterology</i> , 2015, 148, 685-687.	1.3	41
151	Time Course of Bacterial Infection of the Pancreas and Its Relation to Disease Severity in a Rodent Model of Acute Necrotizing Pancreatitis. <i>Annals of Surgery</i> , 1994, 220, 193-198.	4.2	40
152	Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice. <i>Gastroenterology</i> , 2016, 151, 1232-1244.e10.	1.3	40
153	Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. <i>Surgery</i> , 2017, 162, 203-210.	1.9	40
154	International Consensus Guidelines for Risk Factors in Chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 579-585.	1.1	40
155	Intraductal papillary mucinous neoplasms: Does a family history of pancreatic cancer matter?. <i>Pancreatology</i> , 2012, 12, 358-363.	1.1	39
156	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2018, 268, 340-347.	4.2	39
157	Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 272, 357-365.	4.2	39
158	International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 910-918.	1.1	39
159	Fluid CEA in IPMNs: A Useful Test or the Flip of a Coin?. <i>American Journal of Gastroenterology</i> , 2009, 104, 796-797.	0.4	38
160	Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4020-4026.	1.5	38
161	Promoting Effect of a High-Fat/High-Protein Diet in DMBA-Induced Ductal Pancreatic Cancer in Rats. <i>Annals of Surgery</i> , 2001, 233, 688-695.	4.2	37
162	Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. <i>Pancreatology</i> , 2017, 17, 920-926.	1.1	37

#	ARTICLE	IF	CITATIONS
163	Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 3203-3211.	1.5	37
164	Membrane-bound ICAM-1 is upregulated by trypsin and contributes to leukocyte migration in acute pancreatitis. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G1194-G1199.	3.4	36
165	Expression of the Adhesion Molecules Mac-1 and I-Selectin on Neutrophils in Acute Pancreatitis is Protease- and Complement-Dependent. <i>Annals of Surgery</i> , 2001, 233, 371-378.	4.2	35
166	The effect of antecolic versus retrocolic reconstruction on delayed gastric emptying after a classic non-pylorus-preserving pancreaticoduodenectomy. <i>American Journal of Surgery</i> , 2015, 209, 1028-1035.	1.8	34
167	Complete dorsal pancreatectomy with preservation of the ventral pancreas: A new surgical technique. <i>Surgery</i> , 2002, 131, 577-580.	1.9	33
168	Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 658-664.	1.7	32
169	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 607-612.	1.3	32
170	The Fistula Risk Score Catalog. <i>Annals of Surgery</i> , 2022, 275, e463-e472.	4.2	32
171	Subcellular kinetics of early trypsinogen activation in acute rodent pancreatitis. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 274, G71-G79.	3.4	30
172	Cytologic characteristics of circulating epithelioid cells in pancreatic disease. <i>Cancer Cytopathology</i> , 2017, 125, 332-340.	2.4	30
173	Improved Mortality in Necrotizing Pancreatitis with a Multidisciplinary Minimally Invasive Step-Up Approach: Comparison with a Modern Open Necrosectomy Cohort. <i>Journal of the American College of Surgeons</i> , 2020, 230, 873-883.	0.5	30
174	Ductulo-insular Pancreatic Endocrine Neoplasms. <i>American Journal of Surgical Pathology</i> , 2003, 27, 461-468.	3.7	29
175	Major Complications Independently Increase Long-Term Mortality After Pancreatoduodenectomy for Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1984-1990.	1.7	29
176	Cystic Papillary Pattern in Pancreatic Ductal Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 696-701.	3.7	28
177	Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. <i>International Journal of Nanomedicine</i> , 2014, 9, 1891.	6.7	28
178	The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts. <i>Endoscopy International Open</i> , 2016, 04, E391-E396.	1.8	28
179	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 274, e134-e142.	4.2	28
180	Randomized trial of a perioperative geriatric intervention for older adults with cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 12012-12012.	1.6	28

#	ARTICLE	IF	CITATIONS
181	Accurate Prediction of Nodal Status in Preoperative Patients with Pancreatic Ductal Adenocarcinoma Using Next-Gen Nanoparticle. <i>Translational Oncology</i> , 2013, 6, 670-675.	3.7	27
182	A contemporary series of patients undergoing open debridement for necrotizing pancreatitis. <i>American Journal of Surgery</i> , 2014, 208, 324-331.	1.8	27
183	Intraductal Papillary Mucinous Neoplasm of the Pancreas. <i>Annals of Surgery</i> , 2016, 263, 908-917.	4.2	27
184	Lexipafant Fails to Improve Survival in Severe Necrotizing Pancreatitis in Rats. <i>International Journal of Gastrointestinal Cancer</i> , 1998, 23, 101-106.	0.4	26
185	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 160-164.	0.6	25
186	Intraductal Papillary Mucinous Neoplasms of the Pancreas: Strategic Considerations. <i>Visceral Medicine</i> , 2017, 33, 466-476.	1.3	25
187	Telomerase Activity in Periampullary Tumors Correlates With Aggressive Malignancy. <i>Annals of Surgery</i> , 2001, 234, 344-351.	4.2	24
188	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2016, 23, 609-617.	1.5	24
189	Giant Lipoma of the Pancreas: Case Report and Review of Lipomatous Lesions of the Pancreas. <i>Pancreas</i> , 2003, 26, 97-99.	1.1	23
190	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?. <i>Annals of Surgery</i> , 2021, 274, e980-e987.	4.2	22
191	Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 125-131.	1.1	22
192	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 1400-1406.	1.5	22
193	Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. <i>Pancreatology</i> , 2020, 20, 722-728.	1.1	22
194	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. <i>Molecular Imaging and Biology</i> , 2021, 23, 456-466.	2.6	22
195	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. <i>Surgery</i> , 2021, 169, 708-720.	1.9	22
196	Pancreatic Cancer and Androgen Metabolism. <i>Pancreas</i> , 1990, 5, 515-518.	1.1	21
197	Management of intraductal papillary mucinous neoplasms. <i>Current Gastroenterology Reports</i> , 2008, 10, 136-143.	2.5	21
198	Diagnosis and Management of Pancreatic Cystic Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 655-674.	2.2	21

#	ARTICLE	IF	CITATIONS
199	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4027-4034.	1.5	21
200	Choriocarcinoma involving the pancreas as first manifestation of a metastatic regressing mixed testicular germ cell tumor. <i>Modern Pathology</i> , 2004, 17, 1573-1580.	5.5	19
201	Quality assessment of the guidelines on cystic neoplasms of the pancreas. <i>Pancreatology</i> , 2015, 15, 463-469.	1.1	19
202	Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. <i>Scientific Reports</i> , 2016, 6, 20390.	3.3	19
203	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 68-76.	1.7	19
204	Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 1148-1155.	4.2	19
205	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. <i>American Journal of Surgery</i> , 2020, 220, 29-34.	1.8	19
206	Evaluation of Morphology and Microcirculation of the Pancreas by ex vivo and in vivo Reflectance Confocal Microscopy. <i>Pancreatology</i> , 2001, 1, 48-57.	1.1	18
207	Is It Safe to Follow Side Branch IPMNs?. <i>Advances in Surgery</i> , 2014, 48, 13-25.	1.3	18
208	Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. <i>Pancreatology</i> , 2005, 5, 67-74.	1.1	17
209	Intraductal papillary mucinous neoplasms. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 424-429.	2.3	17
210	Surgical management of intraductal papillary mucinous neoplasm with main duct involvement: an international expert survey and case-vignette study. <i>Surgery</i> , 2018, 164, 17-23.	1.9	17
211	Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Plea for Prospective Differentiation Between Main-Duct and Side-Branch Tumors. <i>Annals of Surgical Oncology</i> , 2005, 12, 98-99.	1.5	16
212	A multicenter randomized controlled trial comparing pancreatic leaks after TissueLink versus SEAMGUARD after distal pancreatectomy (PLATS) NCT01051856. <i>Journal of Surgical Research</i> , 2016, 206, 32-40.	1.6	16
213	Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 226-234.	1.7	16
214	The Proteome of Postsurgical Pancreatic Juice. <i>Pancreas</i> , 2015, 44, 574-582.	1.1	15
215	Simulated Volume-Based Regionalization of Complex Procedures. <i>Annals of Surgery</i> , 2021, 274, 312-318.	4.2	15
216	A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 275, 391-397.	4.2	15

#	ARTICLE	IF	CITATIONS
217	Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis. <i>Abdominal Radiology</i> , 2017, 42, 2101-2107.	2.1	14
218	Ex vivo human bile duct radiofrequency ablation with a bipolar catheter. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2808-2813.	2.4	14
219	Assessment of Pancreatic Tumor Resectability with Multidetector Computed Tomography. <i>Academic Radiology</i> , 2008, 15, 1058-1068.	2.5	13
220	Intraductal Papillary Mucinous Neoplasm of the Pancreas. <i>Surgical Clinics of North America</i> , 2016, 96, 1431-1445.	1.5	13
221	Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. <i>Pancreas</i> , 2017, 46, 183-189.	1.1	13
222	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 656-661.	1.3	13
223	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	3.7	13
224	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3898-3912.	1.5	13
225	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	1.1	13
226	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 386-386.	1.6	13
227	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 953-959.	1.7	12
228	Primary lymph node gastrinoma: A single institution experience. <i>Surgery</i> , 2017, 162, 1088-1094.	1.9	12
229	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. <i>Clinical Cancer Research</i> , 2021, 27, 2807-2815.	7.0	12
230	Novel Xenograft and Cell Line Derived From an Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas Give New Insights Into Molecular Mechanisms. <i>Pancreas</i> , 2010, 39, 308-314.	1.1	11
231	Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. <i>Annals of Surgical Oncology</i> , 2021, 28, 4183-4192.	1.5	11
232	Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. <i>Annals of Surgical Oncology</i> , 2021, 28, 4216-4224.	1.5	11
233	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. <i>Surgery</i> , 2021, 170, 1195-1204.	1.9	11
234	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e518-e526.	4.2	11

#	ARTICLE	IF	CITATIONS
235	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3936-3942.	1.5	10
236	Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 897-903.	1.1	10
237	A rat model to study hypercalcemia-induced acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1994, 15, 91-96.	0.4	9
238	Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?. <i>Hpb</i> , 2020, 22, 1020-1024.	0.3	9
239	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020, 77, 35-45.	2.9	9
240	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. <i>Pancreatology</i> , 2020, 20, 691-697.	1.1	9
241	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. <i>Annals of Surgical Oncology</i> , 2021, 28, 4592-4601.	1.5	9
242	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4116-4116.	1.6	9
243	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2022, 32, 2470-2480.	4.5	9
244	Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 116-21.	0.7	9
245	Number of Worrisome Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm. <i>Journal of the American College of Surgeons</i> , 2022, 234, 1021-1030.	0.5	9
246	Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy. <i>Visceral Medicine</i> , 2015, 31, 43-46.	1.3	8
247	Understanding Pancreatic Diseases Using Animated Pancreas Patient. <i>Pancreas</i> , 2018, 47, 1256-1261.	1.1	8
248	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2859-2870.	1.7	8
249	Open Pancreatic Necrosectomy: Indications in the Minimally Invasive Era. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1089-1091.	1.7	7
250	Imaging of pancreatic cystic lesions with confocal laser endomicroscopy: an ex vivo pilot study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 5119-5126.	2.4	7
251	Tumors of the Pancreas. , 2010, , 1017-1034.e4.		7
252	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	1.6	7

#	ARTICLE	IF	CITATIONS
253	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. <i>Surgery</i> , 2022, 171, 1379-1387.	1.9	7
254	A Selective Approach to the Resection of Cystic Lesions of the Pancreas: Results From 539 Consecutive Patients. <i>Annals of Surgery</i> , 2007, 245, 826-827.	4.2	6
255	Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 1606-1612.	1.5	6
256	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	4.2	6
257	Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2014, 6, 136.	1.5	6
258	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1587-e1593.	2.9	6
259	Standardized cytopathology reporting for the pancreas: The time is right. <i>Cancer Cytopathology</i> , 2014, 122, 397-398.	2.4	5
260	Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch-duct IPMN After 10 Years of Surveillance. <i>Annals of Surgery</i> , 2017, 266, e38-e40.	4.2	5
261	Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-operative factors. <i>American Journal of Surgery</i> , 2018, 216, 511-517.	1.8	5
262	Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. <i>Hpb</i> , 2019, 21, 834-840.	0.3	5
263	A Step-Up Approach to Infected Abdominal Fluid Collections: Not Just for Pancreatitis. <i>Surgical Infections</i> , 2020, 21, 54-61.	1.4	5
264	A risk-adjusted analysis of drain use in pancreaticoduodenectomy: Some is good, but more may not be better. <i>Surgery</i> , 2022, 171, 1058-1066.	1.9	5
265	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4118-4118.	1.6	5
266	Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. <i>Annals of Surgery</i> , 2022, 276, 215-221.	4.2	5
267	Surgery of cystic neoplasms. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2002, 12, 803-812.	1.4	4
268	Consensus defining postpancreatectomy complications: An opportunity we cannot ignore. <i>Surgery</i> , 2007, 142, 771-772.	1.9	4
269	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , 2014, 4, e117-e123.	2.1	4
270	To resect or not to resect. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 343-348.	2.3	4

#	ARTICLE	IF	CITATIONS
271	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2019, 32, 844-854.	5.5	4
272	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	1.5	4
273	Microscopic size measurements in postneoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. <i>Histopathology</i> , 2020, 77, 144-155.	2.9	4
274	Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 249-254.	0.5	4
275	ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN). <i>Pancreatology</i> , 2022, 22, 264-269.	1.1	4
276	Surgical Approaches to Benign and Malignant Tumors of the Ampulla of Vater. <i>Surgical Oncology Clinics of North America</i> , 1996, 5, 689-711.	1.5	3
277	Pancreatic Cysts 3 cm or Smaller. <i>Radiology</i> , 2007, 243, 607-608.	7.3	3
278	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4128-4128.	1.6	3
279	Andrew L. Warshaw, MD: Modern pioneer of pancreatic surgery. <i>Surgery</i> , 2012, 152, S1-S3.	1.9	2
280	Can Prognosis Be Modified in Pancreatic Cancer?. <i>Annals of Surgical Oncology</i> , 2020, 27, 632-633.	1.5	2
281	Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapyâ€”Reply. <i>JAMA Surgery</i> , 2020, 155, 269.	4.3	2
282	Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4544-4550.	1.5	2
283	Response to: Re: Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2021, 169, 480-481.	1.9	2
284	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 429-429.	1.6	2
285	Analysis of in court malpractice litigation following pancreatic surgery. <i>Pancreatology</i> , 2021, 21, 819-823.	1.1	2
286	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019, 37, 392-392.	1.6	2
287	In response to Birgir Gudjonsson, MD. <i>Surgery</i> , 2014, 156, 1286.	1.9	1
288	ASO Author Reflections: Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3913-3914.	1.5	1

#	ARTICLE	IF	CITATIONS
289	A pancreatic tail mass in a young male. <i>Gastroenterology</i> , 2021, , .	1.3	1
290	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	1.6	1
291	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4113-4113.	1.6	1
292	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 368-368.	1.6	1
293	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4021-4021.	1.6	1
294	Animal Models of Pancreatic Adenocarcinoma. , 2002, , 323-330.		0
295	â€œHow I do Itâ€•Session of the Pancreas Club. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 725-725.	1.7	0
296	Management of Cystic Neoplasms of the Pancreas. , 2010, , 1125-1139.		0
297	Mujer joven con tumoraci3n quÃstica en la cabeza pancreÃtica. <i>CirugÃa EspaÃola</i> , 2014, 92, 565-567.	0.2	0
298	A Young Woman With a Pancreatic Head Cystic Neoplasm. <i>CirugÃa EspaÃola (English Edition)</i> , 2014, 92, 565-567.	0.1	0
299	2016 American Pancreatic Association Presidential Address. <i>Pancreas</i> , 2016, 45, 1359-1360.	1.1	0
300	Response to Comment on â€œReappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinomaâ€•. <i>Annals of Surgery</i> , 2020, 271, e18-e19.	4.2	0
301	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 439-439.	1.6	0
302	Surgical Management of IPMN. , 2008, , 419-432.		0
303	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 301-301.	1.6	0
304	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4047-4047.	1.6	0
305	Natural History and Malignant Change of Main Duct IPMN. , 2014, , 11-17.		0
306	Timing of Resection of Main-Duct IPMN. , 2014, , 153-161.		0

#	ARTICLE	IF	CITATIONS
307	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
308	Single-nucleus RNA-seq of frozen archival primary pancreatic ductal adenocarcinoma uncovers multi-compartment intratumoral heterogeneity associated with neoadjuvant treatment.. Journal of Clinical Oncology, 2020, 38, 4633-4633.	1.6	0
309	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. Journal of Clinical Oncology, 2020, 38, e24032-e24032.	1.6	0
310	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
311	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. Journal of Clinical Oncology, 2020, 38, 159-159.	1.6	0
312	Surgical Treatment and Long-Term Outcome of Cystic Neoplasms of the Pancreas. , 0, , 932-939.		0
313	Surgical Management of Necrotizing Pancreatitis. , 0, , 308-320.		0
314	Clinical Assessment and Staging of Pancreatic Cancer. , 0, , 643-647.		0
315	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. Cancer Research, 2022, 82, SY12-04-SY12-04.	0.9	0